Latest Hotspot

Lyell Immunopharma Reports Phase 1 Dose-dependent Efficacy of ROR1 CAR-T Therapy LYL797, Boosted by Anti-exhaustion Tech

2 July 2024
3 min read

Lyell Immunopharma, Inc. a clinical-stage company focused on T-cell reprogramming, has unveiled preliminary clinical and translational results from the Phase 1 trial of LYL797. This first-generation ROR1 CAR T-cell product candidate incorporates advanced anti-exhaustion technology and is part of their diverse pipeline of cell therapies targeting solid tumors.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The initial dataset predominantly includes patients with triple-negative breast cancer and showed dose-dependent antitumor clinical activity, as well as the ability of LYL797 CAR T cells to proliferate, infiltrate tumors, and eradicate cancer cells in patients with relapsed/refractory conditions. No cases of immune effector cell-associated neurotoxicity syndrome linked to LYL797 were reported. Pneumonitis was seen in patients with lung metastases, prompting a separate, more gradual dose escalation for these individuals. No dose-limiting toxicities were observed in patients without lung involvement. All patients now receive prophylactic steroids before LYL797 treatment.

“These initial clinical results are promising, showing that LYL797 ROR-1-targeted CAR T cells exhibited dose-dependent antitumor activity and hold the potential for even more substantial and lasting benefits as we proceed with dose escalation,” stated David R. Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute, a medical oncologist, and a principal investigator in the LYL797 study. “Pneumonitis is a recognized complication of radiotherapy and multiple approved cancer therapies, including immune checkpoint inhibitors and various antibody-drug conjugates. We have adopted a protocol using steroids, the standard of care for pneumonitis treatment, which I believe will help us effectively monitor and manage these incidents.”

The LYL797 study includes a comprehensive translational program, revealing for the first time that CAR T cells enhanced with anti-exhaustion technology could expand, persist, and infiltrate solid tumors, sometimes showing evidence of cancer cell destruction. TIGIT, a marker for T cell exhaustion, was assessed in samples collected on Day 11 post-infusion, with only a small fraction of LYL797 CAR T cells being TIGIT-positive. RNAseq data indicated a significant proportion maintained the target phenotypes of stem-like and effector memory cells.

“We are heartened by the clinical responses and the clear dose-dependent antitumor activity observed with LYL797 in patients with advanced triple-negative breast cancer,” said Lynn Seely, MD, President and Chief Executive Officer of Lyell. 

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of July 2, 2024, there are 73 investigational drugs for the ROR1 target, including 75 indications, 59 R&D institutions involved, with related clinical trials reaching 46, and as many as 9698 patents.

LYL-797 targets ROR1 and being developed for the treatment of various cancers and respiratory diseases. The drug has reached Phase 1 in its global development, indicating initial testing in humans to assess its safety and dosage. Further information on the drug's mechanism of action and clinical efficacy will be necessary to fully evaluate its potential impact in the pharmaceutical industry.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Phexxi approved by the FDA?
Drug Insights
3 min read
Is Phexxi approved by the FDA?
2 July 2024
The U.S. Food and Drug Administration (FDA) approved Phexxi on May 22, 2020.
Read →
Simcere Zaiming Announces NMPA Approval of Cetuximab Beta in China
Latest Hotspot
3 min read
Simcere Zaiming Announces NMPA Approval of Cetuximab Beta in China
2 July 2024
Simcere Zaiming, announced that their new anti-EGFR antibody treatment, Enlituo®, has been officially approved for sale by the China National Medical Administration.
Read →
Is Cerianna approved by the FDA?
Drug Insights
3 min read
Is Cerianna approved by the FDA?
1 July 2024
Cerianna (fluoroestradiol F 18) is FDA approved. The U.S. Food and Drug Administration (FDA) approved Cerianna on May 20, 2020.
Read →
Global New Drug Research and Development Progress Weekly Report(6.24-6.30)
Drug Highlight
14 min read
Global New Drug Research and Development Progress Weekly Report(6.24-6.30)
1 July 2024
6.24-6.30 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.